Results 111 to 120 of about 11,689 (208)

The safety of influenza vaccine in clinically cured leprosy patients in China

Human Vaccines & Immunotherapeutics, 2018
Background: Leprosy is an infectious disease caused by the bacterium Mycobacterium leprae. Influenza vaccine is an important influenza prevention strategy and the preparations used display good safety and tolerability profiles. But the safety of applying
Yi Zheng, Li Chen, Jie Zou, Zheng-Gang Zhu, Li Zhu, Jing Wan, Quan Hu   +6 more
doaj   +1 more source

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

, 2008
A multicentre, randomized, phase III clinical trial in 5071 healthy adults was conducted to evaluate the safety and reactogenicity of a 15 microg HA dose of a candidate oil-in-water emulsion-based adjuvant system (AS)-adjuvanted split-virion H5N1 (AS ...
Rombo, L,, Schwarz, TF, Richardus, JH, Rümke, HC, Duval, X, Bayas, J-M, Caso, C, de, Juanes J-R, Campins, M, Romanenko, V   +9 more
core   +1 more source

Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis

Expert Review of Vaccines
Introduction Different COVID-19 vaccines are being utilized as boosters. This systematic review and meta-analysis aims to evaluate the reactogenicity of COVID-19 vaccines given as booster doses, according to vaccine type, dose, timing, participant ...
Alberto San Francisco Ramos, Carolina Liu Sanchez, Tatiana Bovill Rose, David Smith, Natasha Thorn, Eva Galiza, Thahmena Miah, Jennifer Pearce, Cecilia Hultin, Catherine Cosgrove, Yingfen Hsia, Paul T. Heath   +11 more
doaj   +1 more source

Rapid assessment of the reactogenicity of a 2016-2017 seasonal influenza vaccine: results from a feasibility study

, 2019
Background: ​​The European Medicines Agency (EMA) calls for a strategy for enhanced safety surveillance of seasonal influenza vaccines. Objective: We assessed the feasibility of collecting reactogenicity data within one month of the start of the ...
Antoon De Schryver (3376835), Thomas Verstraeten (2266663), Anke L. Stuurman (3376832)   +2 more
core   +1 more source

Reactogenicity of pertussis vaccines. [PDF]

BMJ, 1978
openaire   +2 more sources

Factors associated with vaccine reactogenicity in school aged children and young adults following administration of two protein-based vaccines

, 2011
Aim To identify or exclude factors associated with injection site reactions following immunisation. Methods Literature review identifying key factors of gender, psychological stress, and exercise and injection technique.
Petousis-Harris, Helen
core  

Reactogenicity of live-attenuated Vibrio cholerae vaccines is dependent on flagellins.

, 2010
Cholera is a severe diarrheal disease caused by the motile Gram-negative rod Vibrio cholerae. Live-attenuated V. cholerae vaccines harboring deletions of the genes encoding cholera toxin have great promise for reducing the global burden of cholera ...
Rui, H, Waldor, MK, Ritchie, JM, Bronson, RT, Mekalanos, JJ, Zhang, Y   +5 more
core   +1 more source

Physician Examination Reactogenicity in the 7 Days Following Dose 1 and Dose 2 of Vaccine Pooled Data.

, 2016
Physician Examination Reactogenicity in the 7 Days Following Dose 1 and Dose 2 of Vaccine Pooled Data.
Colin Gelder (3599288), Richard Broughton (3587444), Corey P. Mallett (3599291), Rob Lambkin-Williams (444042), David He (306209), Anthony S. Gilbert (444037), Alex Mann (845560), John S. Oxford (444040), David Burt (3477137)   +8 more
core   +1 more source

STUDY OF SAFETY OF PAROTITIS VACCINE

Журнал микробиологии, эпидемиологии и иммунобиологии, 2015
Aim. Monitoring of post-vaccinal complications in children immunized with a parotitis vaccine. Materials and methods. Observation of198 945 children, immunized with 16 lots of parotitis vaccine with Leningrad-3 strain (L-3), was carried out for 3 years ...
G. M Ignatiev, M. V Kulak, E. V Otrashevskaya, E. K Bukin, A. E Nesterov, M. A Gorbunov, V. N Mikheev   +6 more
doaj  

Frequency of maximum severity of systemic (A) and local (B) reactogenicity symptoms by group in the safety cohort.

Frequency of maximum severity of systemic (A) and local (B) reactogenicity symptoms by group in the safety cohort.
Carlos A. Diazgranados (18182373), Paul Goepfert (117356), Modulakgota Sebe (18182364), Shelly Ramirez (16441662), Erica Andersen-Nissen (8881685), Linda-Gail Bekker (60754), Fatima Laher (238017), Jack Heptinstall (8881679), Nyaradzo M. Mgodi (3331383), Maurine D. Miner (8881676), Portia Hunidzarira (18182361), Lawrence Corey (140058), Nicole Grunenberg (662181), Marguerite Koutsoukos (296151), Olivier Van Der Meeren (8486013), One B. Dintwe (4900906), Laura Polakowski (11798033), Kelly E. Seaton (7163780), Jia J. Kee (18182358), Zoe Moodie (211088), Kathryn Mngadi (795219), Simbarashe Takuva (3815548), Stephen De Rosa (576064), Michelle Nebergall (18182367), Niranjan Kanesa-thasan (8534472), Susan W. Barnett (8072021), Ilesh Jani (563942), Lerato Sikhosana (18182370), Faatima Laher Omar (18182355), Georgia D. Tomaras (7163792), M. Juliana McElrath (8048912), Nivashnee Naicker (325739), James G. Kublin (8173401)   +32 more
core   +1 more source